Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | NPBWR1 | P48145 | 15/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | MITF | O75030 | 1/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | XBP1 | P17861 | 1/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1460616 | 0.83 | GAA (0.54) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9918706 | 0.82 | NPSR1 (0.56) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1462030 | 0.81 | GAA (0.51) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1460657 | 0.80 | NPBWR1 (0.60) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9918819 | 0.80 | NPSR1 (0.53) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1462027 | 0.79 | NPSR1 (0.52) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9917046 | 0.77 | ALDH1A1 (0.50) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1461789 | 0.75 | RAB9A (1.00) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL1461851 | 0.74 | ALDH1A1 (0.47) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL140231 | 0.73 | GAA (0.72) | GAANPBWR1SMN1; SMN2CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-06-22 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-9562019-B2 | Substituted pyridazines as EGFR and/or KRAS inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2017-02-07 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DJABALLAH HAKIM (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120149710-A1 | SORTASE A INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2012-06-14 | — | — | US | disclosed |
| WO-2011028492-A2 | SORTASE A INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-03-10 | — | — | WO | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149710-A1 | SORTASE A INHIBITORS | STS, ENGASE, SPR | GAA 34/4885NPBWR1 2734/4885SMN1; SMN2 3465/4885 |
| US-20130131062-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | GAA 1254/4885NPBWR1 4020/4885SMN1; SMN2 1856/4885 |
| US-20100210649-A1 | PYRIDAZINONES AND FURAN-CONTAINING COMPOUNDS | DPYD, PDXK, TYMP | GAA 1254/4885NPBWR1 4020/4885SMN1; SMN2 1856/4885 |
| US-20170173008-A1 | ANTIMICROBIAL AGENTS AND SCREENING METHODS | BAK1, DCLRE1B, BLVRB | GAA 1994/4885NPBWR1 2859/4885SMN1; SMN2 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.